There was a May 23rd article in the New York Times Sunday magazine entitled " Can the Nervous System Be
Hacked." It goes into depth of the new science of bioelectronics. It is by far the best article I have read regarding
the potential and where I think ETRM fits and how far ahead we may be.
Please, that is just not true. Those folks are out or still owners. This company suffers from terrible IR/PR and management. PYBI had great Phase III data and the stock exploded. MACK had good data and what happened.
Long term capital gains? Hardly.
Stop making excuses for mediocre management. Makes you sound like an employee.
This is the strangest company I have ever owned. It has the first device that is actually a therapeutic, was deemed safe and will be approved. It has cutting edge science in the new field of bioelectronics. We have a good inventory of institutional investors and we traffic in obesity, the worst disease in the U.S.
The quiet is necessary as the FDA has us under review.
Does anyone out there have a comment? This is why I sold all my stock. We have no idea what is happening at MACK and I feel neither does management. If 398 and 121 were so good why is this stock trading here?
Hey FIDO..you own a slug of PBYI. You own a ton of MACK...What are we all missing?
IBM is a POS..The have bought back 1 Billion shares in the last 12 years. Lou Gerstner " two step."
14 quarters of falling revenue. What I meant is that if shares outstanding mattered IBM is the poster child for lowering shares outstanding and beating EPS. GILD has honest accounting and a great product. IBM is a dead company and that moron Buffett is buying it!
Look at the PE and the earnings..Not close to us...GILD will do $8 in the next 12 months..11 PE???
If you worried about shares outstanding you would be buying IBM...
There is a lot more to this company than you or the market appreciates. What else are they working on using their technology? Obesity is just one indication. If you read the New York Times article and saw the money Merck put up to get their feet wet in the bioelectronic space, you have to believe Knudson is not spending time looking for other indications. The FDA will address the device sooner than later and it will become the standard of care. The insurance industry will reimburse as they know the benefits are all downstream.
Do not be so quick to think sale of the company. Once VBLOC gets a head of steam we would be nuts to sell the company. This will be a process and I am loathe to sell our science as there is a lot more we can do.
We are still under Wall Street's radar, but as far as I am concerned the company is like an iceberg. Most of what constitutes Enteromedics is 90% unseen.
Sentiment: Strong Buy
UVA and froig...Don't you guys think this is a great straddle..buy the November 7 1/2 calls and the November 5 puts...He gets a deal the stock will get to $10..If he finances and they get no deal dones the stock goes to $3.00....the Mulroy straddle...
Are you saying I am off base regarding Mulroy??? I am from an investment banking background. Mulroy is from Yale with a degree in divinity. He has no idea who he talks to, does not understand the markets, and keeps spiking the Kool-Aid at Fidelity.
But above all I must add one thing..Now don't go nuts. The Sanofi retreat now is not a problem for me. Those dopes plowed a ton of money into RNAi science through Alnylam. Look at the shares of DRNA and TKMR. TKMR must be trading at cash.
I do not blame MACK for the SNY lunacy. I just blame them for not telling us the truth and making promises they never keep.
I still believe you will see 25 Million shares within a month.They renegotiated the loan agreement. They still have covenants and now they may be tougher. What made MACK borrow $40 Million? What dopey bank lent it to them! The CFO got his MBA at Sears!
There are a lot of great pipelines out there. ALNY has no drugs and works it the hardest therapeutic arena
currently. If you can tell me what year you expect a drug to pass the FDA that Alnylam makes. then I can
assuage your sinking feeling.
The IR/PR at Merrimack is pretty sad. When companies don't keep shareholders on the first page I
get suspect. Maybe they are still coming to grips with the SNY return, but like you said, is the process
(any process) noving along?
Is $5.04....If they do a deal that is where it gets done. If it trades there it is the place to buy. Other than that you buy at $8 after they sell 398 or fire Mulroy!!!!
I am not a scientist. I talk to some but if as you say the results have been " remarkable," the big pharma companies do not seem to think so. I do not know the SNY background for leaving, but they did. MM 398 may be a good drug, but the data has been around long enough for someone to pay attention.
All the recent insiders are underwater from their latest buys. Mulroy has been a disappointment and yet they keep him. MM 398 will not be on the market until 2H 2015. I do not think they have the luxury of time as they keep burning through capital.
Hey I have a lot of pals in this stock. A year and a half ago I bought the stock at $2.45..I also bought it at $4.00 within the last year. This company has to do something away from 398 which they bought for nothing and is not part of the network biology they touted.
They have pitiful IR/PR. The CEO is useless. There is better PR on this message board than the company issues.
The market is awful and even if they do a deal it is not going to be a big one.
You learning that now..The old Lou Gerstner two step...This company is a joke. Negative shareholder equity!!!
The stock would be at $20 if they didn't keep buying but the real fools are the bond buyers. And S&P still has an investment grade rating!